Drug Shortage Report for ACT GABAPENTIN
| Report ID | 20300 |
| Drug Identification Number | 02256142 |
| Brand name | ACT GABAPENTIN |
| Common or Proper name | GABAPENTIN |
| Company Name | ACTAVIS PHARMA COMPANY |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | GABAPENTIN |
| Strength(s) | 100MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
| Packaging size | 500 |
| ATC code | N03AX |
| ATC description | ANTIEPILEPTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2017-08-18 |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2018-10-11 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2018-10-11 | French | Compare |
| v7 | 2018-10-11 | English | Compare |
| v6 | 2018-10-11 | French | Compare |
| v5 | 2018-10-11 | English | Compare |
| v4 | 2017-10-10 | French | Compare |
| v3 | 2017-10-10 | English | Compare |
| v2 | 2017-08-24 | French | Compare |
| v1 | 2017-08-24 | English | Compare |
Showing 1 to 8 of 8